Experimental Virus-Antibody combo for skin cancer shows early promise but trial halted
Disease control
Terminated
This early-phase trial tested a combination of two drugs—a virus-based therapy (talimogene laherparepvec) and an antibody (panitumumab)—in 5 people with advanced skin squamous cell carcinoma that had spread or was hard to treat. The goal was to see if the combination was safe and…
Phase: PHASE1 • Sponsor: Rutgers, The State University of New Jersey • Aim: Disease control
Last updated May 06, 2026 16:04 UTC